BlinkLab
Announcements

Read our recent announcements about our company, our research, and partnerships.

BlinkLab Secures A$17.5M to Fund the Launch of Autism Diagnostic Aid and Expand ADHD Program

BlinkLab successfully completes an oversubscribed placement new shares to sophisticated and institutional investors; raising a total of A$17.5 million (before costs).

•

April 16, 2026

In the news

View all

May 1, 2026

Brian Leedman, Non-Executive Chairman, outlines BlinkLab’s digital biomarker technology and clinical pathway

Read the article

April 28, 2026

How BlinkLab Limited is Building AI Diagnostics for Autism and ADHD – Interview with Mr Brian Leedman

Read the article

April 21, 2026

BlinkLab raises $17.5m towards US approval

Read the article

April 18, 2026

BlinkLab Secures A$17.5M to support the completion of its ongoing US FDA 510(k) registrational trial for autism diagnosis using BlinkLab’s Dx1 platform

Read the article

Read all announcements

BlinkLab Secures A$17.5M to Fund the Launch of Autism Diagnostic Aid and Expand ADHD Program

BlinkLab successfully completes an oversubscribed placement new shares to sophisticated and institutional investors; raising a total of A$17.5 million (before costs).

Apr 16, 2026

Commencement of Pivotal Validation Program for FDA 510(k) Submission: First Participant Enrolled

BlinkLab announced the commencement of its validation program supporting 510(k) submission, with the first child participant now enrolled and having completed initial testing using BlinkLab Dx1.

Mar 24, 2026

BlinkLab Selected for Morocco’s Nationwide Government-Funded Autism Screening Program

BlinkLab announces its involvement in a landmark national autism screening and capacity-building initiative launched by the Kingdom of Morocco.

Mar 23, 2026

Completion of Clinical Trial Network for Pivotal FDA Study with Addition of Tenth Clinical Site – University of Arkansas

BlinkLab announces the onboarding of University of Arkansas as the tenth and final clinical site for the Company’s upcoming pivotal U.S. regulatory trial for BlinkLab Dx 1.

Mar 16, 2026

Partnership with SHANK2 Autism Foundation in the United States

Formation of new partnership with the SHANK2 Foundation, a U.S.-based not-for-profit organisation with a focus on advocacy, awareness, the creation of research infrastructure.

Mar 13, 2026

Expansion of Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement – Drexel Univerisity

BlinkLab announced that Drexel University has joined as a clinical site for the Company’s pivotal U.S. regulatory trial for BlinkLab Dx 1.

Feb 12, 2026

Want to feature BlinkLab?

We are more than happy to assist you with that. If you need any assets, insights or want to request an interview — feel free to reach out to Henk-Jan, our CEO.

Send Henk-Jan an email

BlinkLab
Announcements

BlinkLab Secures A$17.5M to Fund the Launch of Autism Diagnostic Aid and Expand ADHD Program

In the news

Brian Leedman, Non-Executive Chairman, outlines BlinkLab’s digital biomarker technology and clinical pathway

How BlinkLab Limited is Building AI Diagnostics for Autism and ADHD – Interview with Mr Brian Leedman

BlinkLab raises $17.5m towards US approval

BlinkLab Secures A$17.5M to support the completion of its ongoing US FDA 510(k) registrational trial for autism diagnosis using BlinkLab’s Dx1 platform

Read all announcements

BlinkLab Secures A$17.5M to Fund the Launch of Autism Diagnostic Aid and Expand ADHD Program

Commencement of Pivotal Validation Program for FDA 510(k) Submission: First Participant Enrolled

BlinkLab Selected for Morocco’s Nationwide Government-Funded Autism Screening Program

Completion of Clinical Trial Network for Pivotal FDA Study with Addition of Tenth Clinical Site – University of Arkansas

Partnership with SHANK2 Autism Foundation in the United States

Expansion of Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement – Drexel Univerisity

BlinkLab Invited to Present at Simons Foundation Autism Research Initiative (SFARI) Event

BlinkLab Receives $822,205 R&D Tax Incentive Refund

High-Profile Journal Publication Validates BlinkLab's Technology

Want to feature BlinkLab?

Help us improve diagnostic evaluations for autism

Awesome! You're now signed up.

BlinkLabAnnouncements

BlinkLab Secures A$17.5M to Fund the Launch of Autism Diagnostic Aid and Expand ADHD Program

In the news

Brian Leedman, Non-Executive Chairman, outlines BlinkLab’s digital biomarker technology and clinical pathway

How BlinkLab Limited is Building AI Diagnostics for Autism and ADHD – Interview with Mr Brian Leedman

BlinkLab raises $17.5m towards US approval

BlinkLab Secures A$17.5M to support the completion of its ongoing US FDA 510(k) registrational trial for autism diagnosis using BlinkLab’s Dx1 platform

Read all announcements

BlinkLab Secures A$17.5M to Fund the Launch of Autism Diagnostic Aid and Expand ADHD Program

Commencement of Pivotal Validation Program for FDA 510(k) Submission: First Participant Enrolled

BlinkLab Selected for Morocco’s Nationwide Government-Funded Autism Screening Program

Completion of Clinical Trial Network for Pivotal FDA Study with Addition of Tenth Clinical Site – University of Arkansas

Partnership with SHANK2 Autism Foundation in the United States

Expansion of Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement – Drexel Univerisity

BlinkLab Invited to Present at Simons Foundation Autism Research Initiative (SFARI) Event

BlinkLab Receives $822,205 R&D Tax Incentive Refund

High-Profile Journal Publication Validates BlinkLab's Technology

Want to feature BlinkLab?

Help us improve diagnostic evaluations for autism

Subscribe to the newsletter

Awesome! You're now signed up.

BlinkLab
Announcements